Why Is bioAffinity Technologies (BIAF) Stock Up +34.74% Today?
Key Takeaways
- Shares of BIAF surged roughly 34.74% to $11.79 in Friday trading, extending a powerful two-day rally from a prior close of $8.75.
- The primary catalyst is continued momentum from a Hong Kong patent grant for the company's CyPath Lung diagnostic, announced Thursday.
- Secondary drivers include recently regained Nasdaq compliance, a federal healthcare distribution agreement, and expansion into post-treatment lung cancer surveillance.
- The move is being amplified by an extremely thin post-reverse-split share float, which magnifies volatility in both directions.
- Traders are watching commercialization updates, reimbursement traction, and the company's cash position and funding needs.
Opening Summary
bioAffinity Technologies, Inc. (BIAF), a San Antonio, Texas-based biotechnology company focused on noninvasive diagnostics for early-stage lung cancer, extended its explosive rally on Friday. The company's flagship product, CyPath Lung, uses flow cytometry and proprietary artificial intelligence to analyze sputum samples for signs of malignancy. After closing Thursday's session at $8.75, the stock climbed to $11.79 in intraday trading, a gain of about 34.74%. The advance follows Thursday's 63% surge triggered by the announcement of a key international patent grant, with momentum and a thinly traded share structure driving continued buying into Friday's session.
Hong Kong Patent Grant Extends the CyPath Lung IP Moat
The catalyst behind the move is the company's announcement on Thursday that the Hong Kong Intellectual Property Department granted a patent covering the platform technology underlying CyPath Lung. The patent, No. HK40048460, protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum, combined with flow cytometry to detect lung cancer cells.
The grant is significant because it establishes dual intellectual-property protection across Hong Kong and China, where the company already secured a patent in 2025. Management emphasized that Asia accounts for an estimated 1.6 million new lung cancer cases annually — roughly two-thirds of the global total — positioning the region as a substantial potential market. The Hong Kong patent rounds out an international estate that now spans the United States, Europe, Japan, China, Hong Kong, and several other jurisdictions.
In clinical trials, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value for detecting lung cancer in high-risk patients with small, indeterminate nodules. The market reaction reflects investor optimism that a stronger intellectual-property position could support future commercialization in high-incidence Asian markets.
A Thin Float Is Amplifying the Price Action
The scale of the move is also a function of the stock's unusual share structure. Following a 1-for-15 reverse stock split that took effect on August 24, 2026, the company's outstanding share count was reduced to roughly 592,000 shares. With such a limited float, even modest shifts in buying interest can produce outsized percentage moves.
Thursday's trading saw volume spike to more than 25 million shares — many times the stock's typical daily average — a pattern consistent with rapid churn among a small pool of shares. This dynamic cuts both ways: the same thin float that fuels sharp rallies can also accelerate declines once momentum fades. Analysts and traders caution that the move reflects a combination of genuine fundamental catalysts and low-float mechanics rather than a single transformational business event.
A Broader Catalyst Stack Is Supporting Sentiment
Beyond the patent grant, several recent developments have reinforced the bullish narrative around BIAF. Earlier in September, the company announced it was advancing CyPath Lung for surveillance of lung cancer survivors who have completed curative-intent treatment, a potentially recurring-use application aimed at a population of more than 680,000 Americans with a history of lung cancer.
The company also disclosed a nationwide federal healthcare distribution agreement with AvMEDICAL, intended to expand access to CyPath Lung within government healthcare systems, including the Department of Veterans Affairs. Additionally, management regained compliance with Nasdaq's minimum bid price listing requirements, removing a near-term delisting overhang. Chief Executive Officer Maria Zannes presented a corporate update at the H.C. Wainwright Global Investment Conference held September 14–16, further elevating the company's visibility among institutional investors.
Market Context and Trading Activity
The rally in BIAF is company-specific rather than a function of broad sector strength. The move has been driven primarily by the patent announcement and the stock's low-float dynamics, with trading volume running well above its longer-term average. The company's publicly traded warrants (BIAFW) have also gained, reflecting spillover enthusiasm across the company's listed securities.
Technically, the stock has reclaimed levels well above its recent lows, though it remains far below the triple-digit highs it touched in 2025 before a series of reverse splits. The sharp intraday swings underscore the elevated volatility and liquidity-driven price action that have characterized the name in recent weeks.
What Comes Next for BIAF
Looking ahead, investors will be watching whether the company can convert its growing patent portfolio and commercial partnerships into sustained CyPath Lung revenue. While test volume has grown sharply off a small base, the business remains unprofitable, and the company has disclosed a going-concern warning tied to its cash position. The need for additional capital raises a key risk: future equity financings could dilute existing holders, particularly given the stock's currently low share count.
Key upcoming items include further commercialization and reimbursement updates, progress on the post-treatment surveillance application, and any disclosures around funding. The Hong Kong and China patents are strategically valuable but do not by themselves generate near-term revenue, and the surveillance indication has not yet been separately validated. As a result, the near-term outlook hinges on execution and capital availability as much as on the intellectual-property milestones that have driven the recent rally.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a way to explore automated approaches tailored to different market environments. Visit the Trending AI Robots page to discover which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BIAF's Stochastic Oscillator is sitting in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BIAF just turned positive on September 23, 2026. Looking at past instances where BIAF's MACD turned positive, the stock continued to rise in 27 of 34 cases over the following month. The odds of a continued upward trend are 79%.
Following a +76.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIAF advanced for three days, in 119 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIAF as a result. In 76 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 10-day moving average for BIAF crossed bearishly below the 50-day moving average on September 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIAF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.181) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (0.229) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. BIAF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIAF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement